HOME >> BIOLOGY >> NEWS
AVANT to develop an oral anthrax and plague vaccine for U.S. Department of Defense

This release has been updated as of Monday January 21st.

NEEDHAM, MA (January 22, 2003): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the agreement, AVANT may receive in excess of $8 million over a two-year period, covering vaccine development through preclinical testing. AVANT executed the subcontract with DynPort Vaccine Company LLC ("DVC"), the prime contractor for the Defense Department's Joint Vaccine Acquisition Program (JVAP). Headquartered in Fort Detrick, MD, JVAP is the lead Defense Department organization for the development and purchase of vaccines for the U.S. military.

"This contract represents one of the first awards from a major U.S. Department of Defense (DoD) initiative to apply modern biotechnological innovations to the development of vaccines that can offer rapid, effective protection from multiple biological agents," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "Current vaccines against bacterial bioweapons like anthrax (Bacillus anthracis) and plague (Yersinia pestis) require a protracted dosing regimen or provide only limited protection, and each vaccine protects against only a single agent. The Defense Department is looking for new, improved generation vaccines that are effective, single-dose, and can protect against multiple agents. The choice of AVANT to conduct this development program is an important recognition of the strength of AVANT's vaccine and vector technologies for accomplishing these aims."

"This contract is very important to AVANT since it provides non-dilutive funding to the company and it means that AVANT now has over two years of cash and cash equivalents on hand," Dr. Ryan concluded.

Senator Edward M. Kennedy (D-MA), Ranking Dem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-281-2413
Kureczka/Martin Associates
22-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Clinical results with AVANT rotavirus vaccine demonstrate nearly 90% protection in young children
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Wisconsin scientists develop quick botox test
5. Bronfenbrenner book sums up human development
6. Researchers develop fast track way to discover how cells are regulated
7. DuPont developing new protective suits for military, first responders
8. OutFoxed! New research may redefine late-stage cardiac development
9. Computer scientists at UH developing nurturing computers
10. Disease diagnosis, drug development focus of UH profs biochip research
11. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Global ... ... recognition biometrics market to grow at a CAGR of 19.36% during ... scenario and the growth prospects of the global voice recognition biometrics ... the revenue generated from the sales of voice recognition biometrics including ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of ... use, in multiple areas of medicine, due to their differentiating characteristics. Stem cells are ... have the ability to be induced to become tissue or organic-specific cells with special ...
(Date:2/21/2017)... ... February 21, 2017 , ... VetStem Biopharma, Inc ... headquarters laboratory in Poway, California. Based upon 12 years of knowledge gained ... and consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. ...
(Date:2/21/2017)... and VANCOUVER, British Columbia , Feb. ... ) today announced that apatorsen results from two randomized Phase ... Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February 16 ... . Clinical data from trials in bladder and prostate cancers ... in combination with standard-of-care treatments. ...
(Date:2/21/2017)... , Feb. 21, 2017   Logicalis Healthcare Solutions ... IT solutions and managed services provider ( www.us.logicalis.com ), ... Desk for Epic. The new service will help hospital ... resources by giving physicians, nurses and other clinicians immediate ... tier-one support. This will allow hospital IT staff to ...
Breaking Biology Technology:
Cached News: